Cargando…

The ELAVL3/MYCN positive feedback loop provides a therapeutic target for neuroendocrine prostate cancer

Neuroendocrine prostate cancer is a rapidly progressive and lethal disease characterized by early visceral metastasis, poor prognosis, and limited treatment options. Uncovering the oncogenic mechanisms could lead to the discovery of potential therapeutic avenues. Here, we demonstrate that the RNA-bi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ji, Yiyi, Zhang, Weiwei, Shen, Kai, Su, Ruopeng, Liu, Xinyu, Ma, Zehua, Liu, Bo, Hu, Cong, Xue, Yizheng, Xin, Zhixiang, Yang, Yi, Li, Ang, Jiang, Zhou, Jing, Na, Zhu, Helen He, Dong, Liang, Zhu, Yinjie, Dong, Baijun, Pan, Jiahua, Wang, Qi, Xue, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684895/ https://www.ncbi.nlm.nih.gov/pubmed/38016952 http://dx.doi.org/10.1038/s41467-023-43676-3

Ejemplares similares

Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy
por: Ma, Zehua, et al.
Publicado: (2022)

High-throughput drug screening identifies fluoxetine as a potential therapeutic agent for neuroendocrine prostate cancer
por: Chen, Lei, et al.
Publicado: (2023)

SMAD9-MYCN positive feedback loop represents a unique dependency for MYCN-amplified neuroblastoma
por: Tan, Kezhe, et al.
Publicado: (2022)

Comprehensive analysis of androgen receptor status in prostate cancer with neuroendocrine differentiation
por: Su, Ruopeng, et al.
Publicado: (2022)

Extended lymphadenectomy for high-risk prostate cancer in patients with chronic lymphocytic leukemia may not be necessary: a report of two cases
por: Zhu, Yinjie, et al.
Publicado: (2019)

PRKAR2B‐HIF‐1α loop promotes aerobic glycolysis and tumour growth in prostate cancer
por: Xia, Lei, et al.
Publicado: (2020)

Transcriptomic signature defines two subtypes of locally advanced PCa with distinct neoadjuvant therapy benefits
por: Zhu, Yinjie, et al.
Publicado: (2023)

SUMOylation controls the binding of hexokinase 2 to mitochondria and protects against prostate cancer tumorigenesis
por: Shangguan, Xun, et al.
Publicado: (2021)

Surface-enhanced Raman spectroscopy before radical prostatectomy predicts biochemical recurrence better than CAPRA-S
por: Pan, Jiahua, et al.
Publicado: (2019)

Efficacy of neoadjuvant docetaxel + cisplatin chemo-hormonal therapy versus docetaxel chemo-hormonal therapy in patients with locally advanced prostate cancer with germline DNA damage repair gene alterations
por: Chi, Chenfei, et al.
Publicado: (2022)

m(6)A-induced repression of SIAH1 facilitates alternative splicing of androgen receptor variant 7 by regulating CPSF1
por: Xia, Lei, et al.
Publicado: (2022)

Single-cell analysis supports a luminal-neuroendocrine transdifferentiation in human prostate cancer
por: Dong, Baijun, et al.
Publicado: (2020)

The Diagnostic Value of PI-RADS v2.1 in Patients with a History of Transurethral Resection of the Prostate (TURP)
por: Liu, Jiazhou, et al.
Publicado: (2022)

Reciprocal Induction of MDM2 and MYCN in Neural and Neuroendocrine Cancers
por: Tran, Hung N., et al.
Publicado: (2020)

Early Plasma Circulating Tumor DNA as a Potential Biomarker of Disease Recurrence in Non-metastatic Prostate Cancer
por: Fei, Xiaochen, et al.
Publicado: (2023)

Platelet to lymphocyte ratio as an independent prognostic indicator for prostate cancer patients receiving androgen deprivation therapy
por: Wang, Yanqing, et al.
Publicado: (2016)

Data on isoaspartylation of neuronal ELAVL proteins
por: Pulido, Mario A., et al.
Publicado: (2016)

lncRNA LUCAT1/ELAVL1/LIN28B/SOX2 Positive Feedback Loop Promotes Cell Stemness in Triple-Negative Breast Cancer
por: Xia, Li, et al.
Publicado: (2022)

Engineering the MoS(2)/MXene Heterostructure for Precise and Noninvasive Diagnosis of Prostate Cancer with Clinical Specimens
por: Xie, Shaowei, et al.
Publicado: (2023)

Combination of the NRF2 Inhibitor and Autophagy Inhibitor Significantly Inhibited Tumorigenicity of Castration-Resistant Prostate Cancer
por: Zhang, Yong, et al.
Publicado: (2022)

MYCN and the epigenome
por: He, Stanley, et al.
Publicado: (2013)

Serum Pre-Albumin Predicts the Clinical Outcome in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Abiraterone
por: Fan, Liancheng, et al.
Publicado: (2017)

Elavl3 is essential for the maintenance of Purkinje neuron axons
por: Ogawa, Yuki, et al.
Publicado: (2018)

The molecular genetics of nELAVL in brain development and disease
por: Mulligan, Meghan R., et al.
Publicado: (2023)

The prevalence and clinical implication of rare germline deleterious alterations in Chinese patients with prostate cancer: A real‐world multicenter study
por: Fei, Xiaochen, et al.
Publicado: (2021)

LINC00460 Promotes Cutaneous Squamous Cell Carcinoma Progression Through Stabilizing ELAVL1 Protein
por: Xue, Chunli, et al.
Publicado: (2022)

MicroRNA-139-3p Inhibits The Growth And Metastasis Of Ovarian Cancer By Inhibiting ELAVL1
por: Xue, Fang, et al.
Publicado: (2019)

hnRNPs and ELAVL1 cooperate with uORFs to inhibit protein translation
por: Zhang, Jiewen, et al.
Publicado: (2017)

Immune infiltration phenotypes of prostate adenocarcinoma and their clinical implications
por: Ma, Zehua, et al.
Publicado: (2021)

PRKAR2B plays an oncogenic role in the castration-resistant prostate cancer
por: Sha, Jianjun, et al.
Publicado: (2016)

Elavl1 Impacts Osteogenic Differentiation and mRNA Levels of Genes Involved in ECM Organization
por: Kota, Satya K., et al.
Publicado: (2021)

Albumin and Fibrinogen Combined Prognostic Grade Predicts Prognosis of Patients with Prostate Cancer
por: Wang, Yanqing, et al.
Publicado: (2017)

Addiction of MYCN Amplified Tumours to B-MYB Underscores a Reciprocal Regulatory Loop
por: Gualdrini, Francesco, et al.
Publicado: (2010)

HuR (Elavl1) and HuB (Elavl2) Stabilize Matrix Metalloproteinase-9 mRNA During Seizure-Induced Mmp-9 Expression in Neurons
por: Zybura-Broda, Katarzyna, et al.
Publicado: (2018)

HER2 in Breast Cancer Stemness: A Negative Feedback Loop towards Trastuzumab Resistance
por: Nami, Babak, et al.
Publicado: (2017)

Glioma glycolipid metabolism: MSI2–SNORD12B–FIP1L1–ZBTB4 feedback loop as a potential treatment target
por: Dong, Weiwei, et al.
Publicado: (2021)

MYCN is amplified during S phase, and c-myb is involved in controlling MYCN expression and amplification in MYCN-amplified neuroblastoma cell lines
por: Aygun, Nevim, et al.
Publicado: (2019)

CHRM4/AKT/MYCN upregulates interferon alpha-17 in the tumor microenvironment to promote neuroendocrine differentiation of prostate cancer
por: Wen, Yu-Ching, et al.
Publicado: (2023)

Implementation of the plasma MYCN/NAGK ratio to detect MYCN amplification in patients with neuroblastoma
por: Su, Yan, et al.
Publicado: (2020)

MYCN upregulates the transsulfuration pathway to suppress the ferroptotic vulnerability in MYCN-amplified neuroblastoma
por: Floros, Konstantinos V., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_37tln0r6pqvf9j3qddkgp8n4lm